

INDEX	Page no:
Certificate 1	III
Certificate 2	IV
Certificate 3	V
Declaration	VI
Preface	VII
Acknowledgements	X
Index	XIII
Appendix- I: List of Abbreviations	XIX
List of Tables	XXIV
List of Figures	XXV

CHAPTER I

1. Introduction	1
1.1. Inflammation	1
1.1.1. Pathophysiology of inflammation	2
1.1.2. Inflammatory diseases	3
1.1.2.1. Cardio vascular diseases (CVD)	3
1.1.2.2. Neurological disease	4
1.1.2.3. Autoimmune disease (AD)	5
i) Systemic autoimmune diseases	5
ii) Organ specific autoimmune disease	5
1.1.2.4. Rheumatoid Arthritis (RA)	6
1.1.2.5. Cancer	6
1.1.3. Current pharmacologic therapies for the treatment of RA	9
1.1.4. Current pharmacologic therapies for the treatment of cancer	11
a) Traditional therapies for cancer	12
b) Targeted therapies for cancer	13

1.2.	Kinase	16
1.2.1.	Classification of PI3K	17
1.2.2.	Biochemistry of phosphatidylinositol-3-kinase	19
1.2.3.	PI3K signal transduction pathways	21
1.2.4.	Clinical significance for targeting PI3K δ isoform	22
1.2.5.	PI3K inhibitors	23
1.3.	Objectives	29
1.4.	Design strategy	30

CHAPTER II

2.	Designing, Synthesis and Biological evaluation of imidazo-quinoline derivatives as PI3Kδ selective inhibitors.	37
2.1.	Chemistry	40
2.1.1.	Materials and Methods	40
2.1.2.	Importance of imidazo-quinoline in biological system	41
2.1.2.1.	Imidazo-quinoline as therapeutic agent	41
2.1.2.2.	Possible routes for the synthesis of imidazo-quinoline derivatives	44
2.1.3.	General procedure of the synthesis of title compounds 9a-g and 10a-l	46
2.1.3.1.	Detailed stepwise experimental procedure for synthesis title compounds 9a-g & 10a-l	49
2.1.3.2.	Spectral data of intermediate 8a-g	52
2.1.3.3.	Spectral data of final compounds 9a-g & 10a-m	55
2.1.4.	Synthesis of 2-Methoxy-3-pyridyl boronate ester intermediate 16	68
2.1.4.1.	Experimental procedure 2-Methoxy-3-pyridyl	69

boronate ester

2.2.	Biological evaluation	72
2.2.1.	<i>In vitro</i> PI3K inhibitory activity assay	73
2.2.2.	<i>In vivo</i> efficacy studies	69
2.2.3.	Mouse xenograft model to test anti-tumor activity of test compounds	73
2.2.4.	Protocol for collagen induced arthritis (CIA) study in mice	74
2.2.5.	Protocol for pharmacokinetic studies	74
2.2.6.	Protocol for safety pharmacology (Toxicity) study	74
2.2.7.	<i>In vitro</i> CYP inhibition study assay	75
2.2.8.	hERG inhibition assay	76
2.2.9.	Anti-proliferative assay	77
2.2.10.	Docking protocol	77
2.3.	Result and Discussion	77
2.3.1.	<i>In vitro</i> PI3K δ inhibitory activity, selectivity and structure activity relationship (SAR)	78
2.3.2.	Isoform selectivity study of 9c , 10h and 10k	82
2.3.3.	Anti-proliferative activities, CYP (Cytochrome) and hERG inhibition for Compound 10h	83
2.3.4.	<i>In vivo</i> pharmacokinetic (PK) and pharmacodynamics (PD) studies of compound 10h	83
2.3.5.	Safety pharmacology study compound 10h	86
2.3.6.	Molecular modelling study	88
2.4.	Conclusion	89

CHAPTER III

3. Design, Synthesis and Biological evaluation of benzofuran based pyrazolo -pyrimidine derivatives as PI3Kδ selective inhibitors.	90
3.1. Chemistry	93
3.1.1. Materials and Methods	93
3.1.2. Benzofuran in biological system	95
3.1.2.1. Example of bioisosteric replacement	95
3.1.2.2. Benzofuran as therapeutic agent	96
3.1.2.3. General method for preparation of benzofuran	100
3.1.3. General procedure for the synthesis of title compounds 26a-s	101
3.1.3.1. Detailed experimental procedure for the synthesis of benzofuran pyrazolo pyrimidine compounds 26a-s (Scheme 3)	103
3.1.3.2. Spectral data of intermediate 25a-d	106
3.1.3.3. Spectral data of final compounds 26a-s	108
3.1.4. General procedure for the synthesis of 3-iodo-1H-pyrazolo [3, 4- <i>d</i>] pyrimidin-4-amine 27	122
3.1.4.1. Detailed experimental procedure for Synthesis of 27 (Scheme 4)	123
3.2. Biological evaluation	124
3.3.1. <i>In vitro</i> PI3K δ inhibitory activity, selectivity and structure activity relationship (SAR)	125
3.3.2. Isoform selectivity study of selected compounds	125
3.3.3. CYP (Cytochrome) and hERG inhibition for compound 26c and 26h	125
3.3.4. Docking protocol	125

3.4.	Result and Discussion	125
3.3.1.	In vitro PI3Kδ inhibitory activity, selectivity and structure activity relationship (SAR)	125
3.3.2.	Isoform selectivity study of selected compounds	128
3.3.3.	CYP (Cytochrome) and hERG inhibition of 26c and 26h	129
3.3.4.	Molecular modelling study	130
3.4.	Conclusion	131

CHAPTER IV

4.	Design, Synthesis and Biological evaluation of 2,4-disubstituted quinoline pyrazolo-pyrimidine derivatives as PI3Kδ inhibitors.	133
4.1.	Chemistry	135
4.1.1.	Materials and Methods	135
4.1.2.	Positional isomeric substitution examples	136
4.1.3.	Quinoline as therapeutic agent	137
4.1.4.	General procedure of the synthesis of title compounds 37a-j	138
4.1.4.1.	Experimental procedure for Synthesis of 2, 4-disubstituted quinoline pyrazolo-pyrimidine compounds 37a-j (Scheme 5)	140
4.1.4.2.	Spectral data of intermediate 36a-f	142
4.1.4.3.	Spectral data of intermediate 37a-j	143
4.2.	Biological evaluation	154
4.2.1.	<i>In-vitro</i> PI3K inhibitory activity assay	155
4.2.2.	<i>In-vitro</i> CYP inhibition study assay	155
4.2.3.	hERG inhibition	155
4.2.4.	Docking protocol	155

4.3.	Result and Discussion	155
4.3.1.	<i>In vitro</i> PI3K δ inhibitory activity, selectivity and structure activity relationship (SAR)	155
4.3.2.	CYP (Cytochrome) and hERG inhibition of compound 37a-j	157
4.3.3.	Molecular modelling study	158
4.4.	Conclusion	159

CHAPTER V

5.	Overall summary of current investigation and Future plans.	160
5.1.	Overall summary of current investigation	160
5.2.	Future plans	163
6.	References	165
7.	Appendix-II: Spectra (^1H NMR, ^{13}C NMR, ESI-MS/HR-MS, UPLC)	183
8.	Publications and Posters	231
